Resources

BIA’s influence and connect were out in force last week – grasping a timely opportunity to get our key Autumn Budget asks across impactfully to the Chancellor with the clear backing of over 200 member CEOs, and putting on a dynamic, pro-innovation Future of UK Regulation conference, featuring MHRA and NICE CEOs amongst other key stakeholders.

In this blog, Chris Sadler, Development Lead at Astrea Bioseparations Ltd, explores how combining multiple interaction mechanisms in chromatography can unlock new, cost-effective solutions for complex downstream challenges.

Worthwhile investments can be hard to recognise when discussing sustainability initiatives. Let's take a look at five with short payback periods.

As discussion around the Autumn Budget heats up, BIA is leading a unified call to the Chancellor to back the science, the entrepreneurs and the life sciences industry that can fuel transformational growth for the UK economy. Our sector letter highlights key growth levers and indeed the barriers that hold the sector back in already challenging global conditions. 

This blog explores the transformative BIA MAC Leadership Programme (LeaP) — a unique initiative empowering emerging bioprocessing professionals to accelerate their careers and strengthen leadership across the UK life sciences sector. With 76% of participants reporting career progression, LeaP is shaping the next generation of biotech leaders.

This blog explores the key investor insights, policy priorities, and technological breakthroughs shaping the future of UK TechBio, revealing how collaboration, talent, and data are driving the sector from innovation to global endurance.

The UK biotech financing numbers for Q3 are out, showing validation of UK assets but a sector under strain from prolonged global headwinds. Time to double down on investment in innovation as a driver for growth and deploy Industrial Strategy plans with urgency.

From scaling up advanced therapy manufacturing to harnessing the power of digital and automation, Ed Samuel, the new COO of the CGT Catapult, discusses how collaboration and innovation will shape the next phase of the UK’s cell and gene therapy ecosystem.

​​​​​​​Following a landmark TechBio Week, we reflect with some insights from our flagship conference on the transformative potential for growth of technological advances in the sector.

In this blog, Justin Wilson, Withers & Rogers LLP, shares his expert perspective on what the recent patent rulings from the Unified Patent Court (UPC) and the Court of Justice of the European Union (CJEU) mean in practice for biotech and pharma companies.

Find out about how opposition parties are positioning themselves in an increasingly fragmented political landscape, and what it might mean for our sector now and in the long term.

It’s TechBio week and we’re celebrating the UK’s leading role in AI and life sciences with significant investment and interest from global players and our own flagship TechBio UK conference and 2025 report launch. 

In this blog, NRG Therapeutics co-founder and CEO Dr Neil Miller and Parkinson’s UK Director of Research (and Investor Observer to NRG), Professor David Dexter, explore the history of the relationship and the innovation journey to date.

Maddy and Emma from BIA's policy and public affairs team report and reflect on the mood in Liverpool, and pull out the key insights for our sector.

Good to see support for BIA agendas in government messaging as we continue to push for pension fund reform, attracting the best global talent, UK manufacturing resilience and addressing the challenges of scaling.

In this blog, Tom Sheldon, Senior Manager at the Science Media Centre (SMC), explores how scientists and communicators are taking on misinformation head-on — and how the SMC’s work supports both researchers and journalists in helping the public make sense of complex, and sometimes controversial, scientific issues.

Ellie Avni, Senior Director in Employment Tax and Reward at FTI Consulting, explores how the new PISCES platform could reshape EMI and CSOP share option plans – creating fresh opportunities for flexibility and tax-efficient value realisation.

The BIA moves into a new era this week, amidst news from the US on tariffs for UK pharma, UK political party conferences underway and a change in leadership at GSK. It’s full steam ahead for BIA towards a busy Autumn, ensuring that the life science sector stays at the top of the government’s priority list and that our members are represented and connected.

Kirsty Neilson, Programme Manager at IBioIC, explains why she has just launched a new programme – Biotech Innovators: Train to Scale – offering a specialist business support programme for budding bioentrepreneurs.

This is my final CEO update in Newscast after 13 years at the BIA. I take up my new role as Executive Chair of the Office for Life Sciences next Monday. Before I do, I want to thank you - my loyal readers - for engaging with my musings over the years, and for your feedback that has improved this blog and my thinking.